Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Feb 8, 2023
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Germline genetic testing is recommended by the National Cancer Center Network (NCCN) for individuals with a personal history of ovarian cancer, young-onset (\<50 years) breast cancer, and a family history of ovarian cancer or male breast cancer, among others. Recent publications demonstrate that the uptake of genetic testing is under-utilized, overall, and rates are consistently lower in minority populations. EHR-based algorithms will be used to identify patients of two Penn Medicine Ob/Gyn practices for whom genetic testing is recommended based on NCCN guidelines and to test pragmatic meth...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with serous ovarian cancer diagnosed more than two years prior to study contact
- • 2. Patients with breast cancer diagnosed at \<50 years of age more than two years prior to study contact
- • 3. Patients with triple negative breast cancer diagnosed more than two years prior to study contact
- • 4. Unaffected individuals reporting a family history of ovarian cancer
- • 5. Unaffected individuals reporting a family history of male breast cancer
- • 6. Unaffected individuals reporting a family history of breast cancer \<50 years
- Exclusion Criteria:
- • 1. Patients who have previously received genetic counseling and/or testing
About Abramson Cancer Center At Penn Medicine
The Abramson Cancer Center at Penn Medicine is a leading academic institution dedicated to advancing cancer research, treatment, and prevention. As part of the University of Pennsylvania, the center integrates cutting-edge scientific discovery with comprehensive clinical care, offering patients access to innovative therapies and clinical trials. Renowned for its multidisciplinary approach, the Abramson Cancer Center collaborates with experts across various specialties to deliver personalized treatment plans while fostering a supportive environment for patients and their families. Committed to improving outcomes and quality of life for cancer patients, the center is at the forefront of groundbreaking research initiatives and educational programs aimed at transforming cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials